FDA approval brings Enhertu into early breast cancer treatment, boosting response before surgery and cutting recurrence risk ...

New approvals for fam-trastuzumab deruxtecan-nxki establish a potential new standard of care in the neoadjuvant and adjuvant settings for patients with HER2-positive early breast cancer.

New trastuzumab deruxtecan indications cover neoadjuvant and adjuvant treatment ...

The U.S. Food and Drug Administration has approved Enhertu (fam-trastuzumab deruxtecan-nxki) for both the neoadjuvant and ...

AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been approved by the US Food and Drug Administration (FDA) for both the neoadjuvant and adjuvant treatment of patients ...

The approval of the humanized monoclonal antibody trastuzumab in 1998 changed the trajectory of treatment and subsequent outcomes for patients with human epidermal growth factor receptor 2 ...

Trastuzumab deruxtecan-THP was associated with a statistically significant and clinically meaningful improvement in pathologic complete response rate vs standard of care. The DESTINY-Breast11 trial ...

Between September 2007 and January 2009, patients with HER2-positive breast cancer were recruited before therapy with trastuzumab. Individuals with negative HER2 and healthy controls were also ...

SAN ANTONIO, Texas — A decade of data continue to demonstrate that adding trastuzumab (Herceptin, Genentech) to standard chemotherapy in women with HER2-positive breast cancer improves both overall ...